Based on previous work that established that HDACi can enhance Fas sensitivity [30] and that IRF-8 expression was required for response to Fas killing [16], [17], we tested the hypothesis that tumor-cell expression of IRF-8 was required for Fas-induced death following HDACi treatment. This evidence concerns the gene IRF8 and neoplasm.